MDMark Onsy Dimitry

Mark Onsy Dimitry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark Onsy Dimitry has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Eman A. Awadallah

    Department of Clinical and Chemical Pathology, National Research Center, Cairo, Egypt

    2 shared publications
  • Eman M. Hassan

    Department of Clinical and Chemical Pathology, National Research Center, Cairo, Egypt

    2 shared publications
  • Hala M. Raslan

    Cardiology Unit, Department of Internal Medicine, National Research Center, Cairo, Egypt

    2 shared publications
  • Rasha N. Yousef

    Department of Clinical and Chemical Pathology, National Research Center, Cairo, Egypt

    2 shared publications
  • Reem I. ElKorashy

    Pulmonary Vascular Disease Unit, Department of Pulmonology, Cairo University, Cairo, Egypt

    2 shared publications
  • Solaf A. Kamel

    Department of Clinical and Chemical Pathology, National Research Center, Cairo, Egypt

    2 shared publications

Latest Publications

  • Open Access

    Circulating miR-16-5p and miR-21-5p in the early post-acute interval of acute myocardial infarction: phase-specific expression and early clinical assessment

    by Mark Onsy Dimitry, Solaf Ahmed Kamel, Eman Mahmoud Hassan, Rasha Nazih, Sally M. Hafez, Amira Fawzy Soliman, Victor Fadlallah Francis, Eman Awadallah

    Background: microRNAs show dynamic responses after acute myocardial infarction (AMI). The early post-acute interval (24–48 h after symptom onset) represents a transition from acute injury to early inflammatory signaling and constitutes a clinically relevant interval in which ventricular function and clinical stability are commonly reassessed. This study evaluated the discriminatory profile of circulating miR-16-5p and miR-21-5p during the early post-acute interval and examined their relationship with early ventricular function and clinical stability. Methods: This cross-sectional study included 60 AMI patients and 30 healthy controls. Plasma miR-16-5p and miR-21-5p were quantified during 24–48 h post AMI using qRT-PCR and normalized to miR-103 as the endogenous control. Relative expression was calculated using the 2^–ΔΔCt method. LVEF and clinical stability were assessed during the same interval. Results: Both miR-16-5p and miR-21-5p were significantly elevated in AMI patients compared with controls ( p = 0.003 and p < 0.001, respectively). Receiver operating characteristic (ROC) analysis demonstrated a strong discriminatory accuracy for miR-21-5p (AUC = 0.88, 95% CI 0.80–0.95) and a modest accuracy for miR-16-5p (AUC = 0.73, 95% CI 0.62–0.83). Neither microRNA showed a significant association with LVEF or clinical stability ( p > 0.05). Conclusion: miR-16-5p and miR-21-5p are significantly elevated during the early post-acute interval of AMI, reflecting a distinct phase-specific molecular profile. miR-21-5p showed stronger discriminatory differences than miR-16-5p, indicating a more robust molecular signal during this phase. The absence of associations with LVEF or short-term clinical status suggests that these microRNAs reflect ongoing molecular activity rather than early functional impairment, with limited utility for early clinical risk assessment.

  • Open Access

    Genomic and clinical predictors of cardiovascular disease in Familial dyslipidemia: risk stratification in Egyptian adolescents and young adults

    by Ammal M. Metwally, Nesma M. Elaraby, Wafaa M. Ezzat, Mark O. Dimitry, Ghada A. Elshaarawy, Neveen A. Ashaat, Ashraf Reda, Ahmed Bendary, Mohamed H. Abbas, Tarek R. El Mawardy, et al.

    Familial dyslipidemia (FD), particularly familial hypercholesterolemia (FH), is a major contributor to premature cardiovascular disease (CVD), especially in regions with high consanguinity and underutilized genetic screening, such as Egypt. This study aimed to assess clinical, biochemical, and genetic factors that differentiate FD patients with and without CVD, and to develop a composite risk score for individualized stratification. A cross-sectional study was conducted on 60 Egyptian patients aged 15–25 years with genetically confirmed FD, equally divided based on CVD status. All participants underwent detailed clinical assessment, lipid profiling, and targeted next-generation sequencing of LDLR , APOB , and PCSK9 genes. Missense variants were evaluated using SIFT, PolyPhen-2, CADD, and ΔΔG stability scores, and classified according to ACMG criteria. Compared to non-CVD patients, those with CVD had significantly higher triglyceride levels (median: 356.5 vs. 236.5 mg/dL; p < 0.001) and a higher frequency of heterozygous pathogenic LDLR variants (30.0% vs. 3.3%; p = 0.006), while homozygous variants were more common in non-CVD patients (26.7% vs. 0%; p = 0.002). Deleterious missense variants were notably more frequent in the CVD group (56.7% vs. 10.0%; p < 0.001). A 10-variable composite risk score integrating clinical, lipid, and bioinformatic predictors effectively distinguished high- and moderate-risk cases (AUC = 0.742; p = 0.022), with 89.5% sensitivity and 81.8% negative predictive value. The study highlights the importance of combining clinical and genomic data for early risk stratification and introduces a pragmatic tool for identifying high-risk youth in resource-limited, consanguineous populations.

  • Open Access

    Role and predictive value of microRNAs 204 and 210 in the diagnosis of pulmonary arterial hypertension and the distinction between idiopathic, systemic sclerosis, and schistosomiasis-associated pulmonary arterial hypertension

    by Mark O. Dimitry, Yosef M. Amin, Reem I. ElKorashy, Hala M. Raslan, Solaf A. Kamel, Eman M. Hassan, Rasha N. Yousef, Eman A. Awadallah

    Background: Pulmonary arterial hypertension is most of the time diagnosed late in the course of the disease and necessitates right cardiac catheterization which is an invasive and costly tool. MicroRNAs have a role in the pathogenesis of pulmonary hypertension, systemic sclerosis, and schistosomiasis and their dosages are easy and non-expensive. Therefore, determining their levels in the blood may be helpful in detecting PAH and differentiating its idiopathic form from those caused by systemic sclerosis and schistosomiasis. Purpose of the study: To evaluate the role of microRNA (miR) 204 and miR-210 in the diagnosis of PAH and to distinguish between idiopathic PAH (IPAH), systemic sclerosis-associated PAH (SSc-PAH), and schistosomiasis-associated PAH (Sch-PAH) and to identify patients who may benefit from simple non-expensive and non-invasive methods in diagnosis of PAH. Methods: Sixty patients with PAH and 30 subjects as control were enrolled in the study. PAH was diagnosed by right heart catheterization, echocardiography, and laboratory tests. Blood samples were taken from all patients for measuring miR-204 and miR-210. Results: MiR-204 was downregulated in PAH and there was a highly significant difference between PAH and control (p = 0.003) with cut-off predictive value ≤ 0.15 µM and 70% sensitivity, 85% specificity with AUC (0.749). However, miR-204 failed to distinguish between IPAH, SSc-PAH, and Sch-PAH. MiR-210 was upregulated in PAH with a highly significant difference between PAH and control (p < 0.001) with cut-off predictive value ≥ 1.16 µM and 93.33% sensitivity, 85% specificity with AUC (0.917). MiiR-210 showed a significant difference between SSc-PAH and idiopathic PAH (P = 0.012) and between SSc-PAH and Sch-PAH (P = 0.035). Conclusions: MiR-204 and miR-210 are useful non-invasive and non-expensive markers for the diagnosis of PAH, miR-210 is an excellent predictor in the diagnosis of PAH and also miR-210 might be used to distinguish SSc-PAH from idiopathic PAH and Sch-PAH.


  • Open Access

    Role of micro-RNAs 21, 124 and other novel biomarkers in distinguishing between group 1 WHO pulmonary hypertension and group 2, 3 WHO pulmonary hypertension

    by Mark O. Dimitry, Youssef M. A. Soliman, Reem I. ElKorashy, Hala M. Raslan, Solaf A. Kamel, Eman M. Hassan, Fatma Elzahraa Ahmed, Rasha N. Yousef, Eman A. Awadallah

    Background: Pulmonary hypertension “PH” is considered a serious cardiovascular disease. World Health Organization divided PH into groups depending on many factors like pathological, hemodynamic, and clinical pictures. Lately, various micro-RNAs “miRNAs” and other novel biomarkers like endoglin and asymmetric dimethylarginine “ADMA” might have a role in diagnosis of PH and may differentiate between pulmonary arterial hypertension “PAH” and non-PAH. The purpose of the study is to show the role of miR-21, miR-124, endoglin and ADMA in the diagnosis of PH and distinguishing between WHO group 1 PH and WHO group 2 and 3 PH and to identify patients who might benefit from non-invasive and inexpensive tools to diagnose PAH. Results: miR-21 was upregulated in group 1 PH, and there was significant difference between group 1 PH as compared with group 2 PH, group 3 PH and control; miR-124 was down-regulated in group 1 PH with highly significant difference between group 1 and group 2 PH and control but no significant difference with group 3 PH, endoglin was elevated in group 1 PH with a significant difference as compared to group 2 PH, group 3 PH and control. ADMA was elevated in group 1 PH as compared to control; however, there was no significant difference between it and group 2, 3 PH. Conclusions: miR-21, miR-124, endoglin and ADMA are good biomarkers to diagnose PH; however, only miR-21 and endoglin could distinguish group 1 PH from group 2 and 3 PH.